Related Experiment Videos
[Treatment of hypertriglyceridemia. Current aspects]
M Malaguarnera1, I Giugno, P Ruello
1Istituto di Medicina Interna e Geriatria, Università, Catania. malaguar@mbox.unict.it
Recenti Progressi in Medicina
|August 10, 2000
Summary
Hypertriglyceridemia contributes to atherosclerosis through various mechanisms. Effective treatments include lifestyle changes and medications like statins, fibrates, and omega-3 fatty acids, particularly for resistant cases.
Area of Science:
- Cardiology
- Metabolic Disorders
- Pharmacology
Background:
- Hypertriglyceridemia is linked to atherosclerosis via low HDL-c, altered LDL-c quality, hemostasis changes, and comorbidities like obesity and hypertension.
- It presents as primary (genetic) or secondary (metabolic disease consequence), necessitating tailored treatment approaches.
Purpose of the Study:
- To review the physiopathology of hypertriglyceridemia in atherosclerosis.
- To outline treatment strategies, including diet and pharmacotherapy.
- To discuss the roles of various drugs in managing hypertriglyceridemia.
Main Methods:
- Literature review of hypertriglyceridemia's role in atherosclerosis.
- Analysis of treatment guidelines and pharmacological interventions.
- Comparison of drug efficacy in reducing triglyceride levels.
Main Results:
- Hypertriglyceridemia involves multiple atherothrombotic pathways.
- Treatment is recommended for diet-resistant cases and those with additional risk factors.
- Key drugs include omega-3 fatty acids, nicotinic acid, fibrates, and statins.
Conclusions:
- Pharmacological therapy for hypertriglyceridemia is reserved for resistant cases and high-risk individuals.
- Specific drugs like acarbose, atorvastatin, and cerivastatin show efficacy in reducing triglycerides and VLDL synthesis.